Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Short-term Investments: 2010-2024

Historic Short-term Investments for Iovance Biotherapeutics (IOVA) over the last 7 years, with Dec 2024 value amounting to $208.1 million.

  • Iovance Biotherapeutics' Short-term Investments was N/A to $142.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $142.7 million, marking a year-over-year change of. This contributed to the annual value of $208.1 million for FY2024, which is 26.13% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Short-term Investments stood at $208.1 million for FY2024, which was up 26.13% from $165.0 million recorded in FY2023.
  • In the past 5 years, Iovance Biotherapeutics' Short-term Investments ranged from a high of $208.1 million in FY2024 and a low of $165.0 million during FY2023.
  • Moreover, its 2-year median value for Short-term Investments was $186.5 million (2023), whereas its average is $186.5 million.
  • Data for Iovance Biotherapeutics' Short-term Investments shows a peak YoY grew of 26.13% (in 2024) over the last 5 years.
  • Over the past 2 years, Iovance Biotherapeutics' Short-term Investments (Yearly) stood at $165.0 million in 2023, then climbed by 26.13% to $208.1 million in 2024.